Revenue segments as reported by the company.

Diagnostics

Drug Development

Intercompany eliminations and other

Biopharma Laboratory Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative expenses

Amortization of intangibles and other assets

Goodwill and other asset impairments

Restructuring and other charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Labcorp Holdings Inc

Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Labcorp posts strong Q4 results, eyes growth amid strategic moves

Labcorp's Q4 performance reflects resilience and growth potential in Diagnostics and Drug Development
Strategic initiatives and spinoff plans position Labcorp for future success and market leadership
Challenges in cost management and revenue growth require focused strategies for sustainable growth
Opportunities lie in capital deployment, market expansion, and operational enhancements for Labcorp

Labcorp reports strong Q1 results, eyes growth amid challenges

Labcorp's Q1 2023 performance was strong, driven by Diagnostics base business revenue growth and strategic initiatives.
While facing challenges like margin constraints and revenue declines in Drug Development, Labcorp is focusing on sustained growth and market opportunities.
The company's emphasis on digital health, upcoming Investor Days, and robust M&A pipeline showcase a proactive approach to future growth.
Labcorp's cautious optimism for SALSA approval and continued advocacy for legislation position it well for potential impacts and future developments.

Labcorp reports robust Q2 earnings, eyes global expansion opportunities

Labcorp's Q2 performance was strong, with revenue growth and strategic initiatives driving positive results.
Challenges such as supply constraints and margin expectations were addressed, with a focus on capital allocation and growth opportunities.
The company remains optimistic about future prospects, with expansion plans, enhanced disclosures, and consistent guidance for segments.
Investor Day scheduled for September to provide more insights, reflecting Labcorp's commitment to transparency and growth.

Labcorp reports robust Q3 earnings, eyes growth amid regulatory challenges

Labcorp's Q3 performance was strong, with a focus on revenue growth, strategic partnerships, and new test introductions. Despite challenges from regulatory impacts, the company remains optimistic about driving substantial shareholder value through growth opportunities and cost-saving initiatives.

LabCorp reports robust Q4 earnings, eyes growth in strategic areas

LabCorp's Q4 call showcased strong financials, strategic partnerships, and innovative offerings. Challenges include pricing issues in Biopharma and COVID impacts on Diagnostics. Opportunities for growth through capital allocation and focus on larger pharma in Biopharma.

LabCorp reports robust Q1 earnings, eyes margin improvement in 2024

LabCorp's Q1 2024 earnings call highlighted strong financial performance, strategic acquisitions, and plans for margin improvement. Despite challenges in certain business areas, the company remains focused on profitable growth and innovation in specialty testing.

Labcorp reports robust Q2 earnings, eyes growth through innovation

Labcorp's Q2 2024 earnings reflect a strong performance, marked by revenue growth, strategic acquisitions, and innovation in healthcare solutions.
While facing challenges in certain segments, Labcorp's focus on expansion, new tests, and digital solutions positions it well for future growth and market leadership.
With a clear outlook for growth and a commitment to advancing healthcare, Labcorp remains a key player in the diagnostics and biopharma laboratory services industry.

Labcorp reports robust Q3 earnings, eyes growth through strategic partnerships

Labcorp's Q3 2024 performance reflects strong revenue growth and profitability, driven by Diagnostics and Biopharma services.
Despite challenges such as regulatory delays, the company remains focused on strategic growth initiatives and operational efficiency.
With a positive outlook for continued growth, Labcorp's emphasis on partnerships, innovation, and cost-saving measures bodes well for its long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

LabCorp (LH) delivered earnings and revenue surprises of 58.98% and 4.70%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

LabCorp (LH) Beats Q3 Earnings and Revenue Estimates

Shares of Laboratory Corp (NYSE:LH) moved higher by 0.5% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 190.00% over the past year to $8.41, which beat the estimate of $5.25.

Recap: Laboratory Corp Q3 Earnings

BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp (or the Company) (NYSE: LH) today announced results for the third quarter ended September 30, 2020. “LabCorp remains committed to fighting the pandemic through innovations in testing and clinical trials aimed at discovering treatments and vaccines. This combined with the dedication from our employees, advances our goal of improving health and improving lives. We delivered strong results in the quarter, with growth across both our Diagnostics and Drug D

LabCorp Announces 2020 Third Quarter Results

Under the extended alliance, LabCorp (LH) expects to expand its COVID-19 test capacity in the Seattle area.

LabCorp (LH) Extends Pact With Swedish for Coronavirus Lab Service

LabCorp (LH) closed the most recent trading day at $203.16, moving -1% from the previous trading session.

LabCorp (LH) Dips More Than Broader Markets: What You Should Know

In Q3, LabCorp (LH) significantly expands accessibility of PCR testing to reach underserved communities.

Higher Testing Volume to Aid LabCorp's (LH) Q3 Earnings

BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, today announced new capabilities that will transform the clinical trial experience with the goal of streamlining the drug development process. This transformation will enable LabCorp's drug development business, Covance, a global leader in decentralized clinical trials (DCTs), to quickly and efficiently connect patients to clinical

LabCorp Transforms the Clinical Trial Experience And Streamlines the Drug Development Process

BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, and Swedish, the largest nonprofit healthcare system in the Puget Sound region, today announced an agreement to extend their more than 20-year relationship. LabCorp will continue to provide laboratory services, both onsite and reference, to the Swedish main hospital campuses as well as the Swedish ambulatory network across the regi

LabCorp and Swedish Extend Laboratory Services Relationship, Providing Continued Access to High-Quality Diagnostics and COVID-19 Testing

BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care, today announced a test that provides a quantitative measurement of an individual's SARS-CoV-2 IgG antibodies. LabCorp's Cov2Quant™ IgG test, which is available only for use in clinical trials and research, was developed to specifically detect and quantify antibodies to SARS-CoV-2, the virus that causes COVID-19. The level of antibodies is an

LabCorp Launches Quantitative Antibody Test to Assess Effectiveness of COVID-19 Vaccines in Clinical Trials

Abbott Labs

Quest Diagnostics

Hologic

QuidelOrtho Corp

Our indicative theme of Covid-19 Testing Stocks, which includes medical devices and diagnostic companies that are involved in Covid-19 testing - is up by about 69% year-to-date, significantly outperforming the S&P 500 which is up by about 8% over the same period. Testing is viewed as key to.

Covid Testing Stocks To Watch As The Holidays Near

LabCorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will LabCorp (LH) Beat Estimates Again in Its Next Earnings Report?

BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, and The Commons Project, a non-profit public trust dedicated to building global digital services and platforms for the common good, today announced a strategic partnership to allow people to securely access their LabCorp test results via CommonHealth, the privacy-preserving Android app that enables users to safely collect, store, a

LabCorp Is First to Provide Consumers With Secure Access to Their Diagnostic Test Results Through CommonHealth

BURLINGTON, N.C. & EDISON, N.J.--(BUSINESS WIRE)--LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, and HealthEC, LLC, a leading provider of population health management solutions, today announced the launch of LabCorp’s Care Intelligence Oncology Module (Oncology Care Module). LabCorp’s Oncology Care Module is designed to empower oncologists to improve patient outcomes and achieve cost-savings by making it easier

LabCorp and HealthEC Launch Transformative Oncology Care Module

According to LabCorp (LH), this process traps viral particles, eliminating the need for RNA extraction reagents.

LabCorp Heat Extraction COVID-19 Test Method Gets FDA's EUA

NEW YORK & BURLINGTON, N.C.--(BUSINESS WIRE)--CLEAR, the secure identity company, and LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, today announced a partnership to enable users of CLEAR’s Health Pass mobile app to securely link their LabCorp test results using their LabCorp Patient™ account. The partnership brings together LabCorp’s advanced testing capabilities, including its COVID-19 tests, with CLEAR’s safe

CLEAR Adds LabCorp COVID-19 Test Results to “Health Pass” Mobile App

LabCorp. LH, -0.72% said Friday it has been granted an emergency use authorization from the U.S. Food and Drug Administration for a new type of molecular test for COVID-19. The new test uses heat and technology to extract RNA from samples collected for COVID-19 testing and can improve the efficiency of testing, the company said in a statement.

LabCorp gets emergency use authorization for new type of COVID-19 molecular test

BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, today announced that it is the first commercial laboratory to receive an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a new, high-throughput method that uses heat and technology to extract RNA from samples collected for COVID-19 molecular testing. The advancement will help the company impro

LabCorp COVID-19 Molecular Test Innovation Receives FDA Authorization

There has been a steady recovery in the Base Business of LabCorp (LH).

LabCorp Coronavirus Test Sales Aid Growth Amid Volume Woes

BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp (NYSE: LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, and Infirmary Health, the largest non-governmental health care system in Alabama, today announced that they have entered into a multi-year collaboration to provide laboratory services to patients and providers throughout the eastern Gulf Coast region. LabCorp, which has a long-standing presence in Alabama through laboratory facilit

LabCorp and Infirmary Health Form Strategic Partnership to Provide Laboratory Services Across Healthcare System

BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp (NYSE: LH) will release its third quarter of 2020 financial results before the market opens on Tuesday, Oct. 27, 2020, and then will host a conference call and webcast beginning at 9:00 a.m. EDT to discuss the results. The earnings release and accompanying financial information will be posted on the LabCorp Investor Relations website. Interested parties can access the conference call by dialing 1-877-898-8036 within the U.S. and Canada, or 1-720-634-28

LabCorp to Announce Third Quarter Financial Results on October 27, 2020

Genfit - ADR

Genfit SA (NASDAQ: GNFT) shot up on Monday after the company announced an agreement with Lab Corporation of America Holdings (NYSE: LH).

Genfit and Lab Corp Partner Up For NASH Liver Test

GENFIT and LabCorp Sign Exclusive Agreement to Commercialize a Novel Diagnostic Test for Liver Disease

This development comes on the heels of LabCorp's (LH) commercial partnership with non-invasive liquid biopsy platform developer, Resolution Bioscience.

LabCorp Boosts Oncology Offerings With Resolution ctDx Launch

BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp (NYSE:LH), a leading global life sciences company that is focused on advancing health and guiding patient care decisions, has launched a new, non-invasive test for patients with non-small cell lung cancer (NSCLC). Resolution ctDx Lung™ is a fast and accurate liquid biopsy test that was developed and will be run by Resolution Bioscience. The test is performed on a standard blood sample and detects actionable mutations in genes associated with NSCLC, pro

News for Labcorp Holdings Inc Stock (LH)